Prognostic Value of Tumor-infiltrating FoxP3+ T Cells in Gastrointestinal Cancers: a Meta Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 May 16

PMID 24827118

Citations 44

Authors

Yong Huang

Huaiwei Liao

Yong Zhang

Rongfa Yuan

Fengmei Wang

Yingtang Gao

Peng Wang

Zhi Du

Affiliations

Soon will be listed here.

Abstract

Purpose: Tumor-infiltrating FoxP3+ T cells have been reported in various human tumors, which impaired cell-mediated immunity and promoted disease progression. However, its prognostic value for survival in patients with different gastrointestinal cancers [hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC)] remains controversial.

Methods: Relevant literature was searched using PubMed, Embase, Cochrane, Ovid Medline and Chinese wanfang databases. A meta-analysis was conducted to estimate pooled survival and recurrence ratios. The odds ratio (OR) and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.

Results: For HCC and GC, the overall survival at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were lower than low FoxP3+ T cells infiltration patients (P<0.05). The recurrences at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were higher than low FoxP3+ T cells infiltration patients (P<0.001). But for CRC, the overall survival at 1, 3 and 5-year of high FoxP3+ T cells infiltration patients were higher than low FoxP3+ T cells infiltration patients (P<0.001). There were no differences in 1, 3 and 5-year recurrences between high and low FoxP3+ T cells infiltration patients (P>0.05).

Conclusions: Our findings suggested that tumor-infiltrating FoxP3+ T cells were a factor for a poor prognosis for HCC and GC, but a good prognosis for CRC.

Citing Articles

Erythrocyte modified controlling nutritional status as a biomarker for predicting poor prognosis in post-surgery breast cancer patients.

Hu J, Dong J, Yang X, Ye Z, Hu G Sci Rep. 2025; 15(1):2071.

PMID: 39814814 PMC: 11736028. DOI: 10.1038/s41598-024-83729-1.

Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.

Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.

PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.

The prognostic value of Forkhead box P3 regulatory T cells in biliary tract cancer: A systematic review and meta-analysis.

Cai P, Wu Z, Yang X, Wang N, Yang Y Medicine (Baltimore). 2023; 102(50):e36608.

PMID: 38115302 PMC: 10727656. DOI: 10.1097/MD.0000000000036608.

Tumor-Infiltrating Lymphocytes and Adoptive Cell Therapy: State of the Art in Colorectal, Breast and Lung Cancer.

Zemanek T, Nova Z, Nicodemou A Physiol Res. 2023; 72(S3):S209-S224.

PMID: 37888965 PMC: 10669950. DOI: 10.33549/physiolres.935155.

Decoding Immune Signature to Detect the Risk for Early-Stage HCC Recurrence.

Devan A, Nair B, Aryan M, Liju V, Koshy J, Mathew B Cancers (Basel). 2023; 15(10).

PMID: 37345066 PMC: 10216348. DOI: 10.3390/cancers15102729.

References

Chen K, Lin S, Zhou L, Xie H, Zhou W, Taki-Eldin A . Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis. PLoS One. 2011; 6(9):e24671. PMC: 3173477. DOI: 10.1371/journal.pone.0024671. View

Sinicrope F, Rego R, Ansell S, Knutson K, Foster N, Sargent D . Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009; 137(4):1270-9. PMC: 2873775. DOI: 10.1053/j.gastro.2009.06.053. View

Chang K . Regulatory T cells and the liver: a new piece of the puzzle. Hepatology. 2005; 41(4):700-2. DOI: 10.1002/hep.20678. View

Wu H, Chen P, Liao R, Li Y, Yi Y, Wang J . Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol. 2012; 27(8):1312-9. DOI: 10.1111/j.1440-1746.2012.07130.x. View

Sakaguchi S . Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005; 6(4):345-52. DOI: 10.1038/ni1178. View

Perrone G, Ruffini P, Catalano V, Spino C, Santini D, Muretto P . Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008; 44(13):1875-82. DOI: 10.1016/j.ejca.2008.05.017. View

Liu J, Gao W, Kang Q, Zhang X, Yang S . Prognostic value of survivin in patients with gastric cancer: a systematic review with meta-analysis. PLoS One. 2013; 8(8):e71930. PMC: 3732238. DOI: 10.1371/journal.pone.0071930. View

Shu P, Qin J, Qin X, Sun Y, Shen Z, Wang Y . [Expression and prognostic value of M2 macrophages and regulatory T cells in gastric carcinoma tissue]. Zhonghua Wei Chang Wai Ke Za Zhi. 2011; 14(5):368-71. View

Huang Y, Wang F, Wang Y, Zhu Z, Gao Y, Ma Z . Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 29(4):851-9. DOI: 10.1111/jgh.12418. View

10.

Lin S, Chen K, Xu Z, Chen H, Zhou L, Xie H . Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells. Cancer Prev Res (Phila). 2013; 6(6):594-602. DOI: 10.1158/1940-6207.CAPR-12-0379. View

11.

Li S, Peng Q, Ding T, Xu J, Zhang C, Feng K . [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi. 2008; 30(7):523-7. View

12.

Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T . FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res. 2007; 13(3):902-11. DOI: 10.1158/1078-0432.CCR-06-2363. View

13.

Shen S, Liang L, Peng B, He Q, Kuang M, Lai J . Foxp3+ regulatory T cells and the formation of portal vein tumour thrombus in patients with hepatocellular carcinoma. Can J Surg. 2011; 54(2):89-94. PMC: 3116706. DOI: 10.1503/cjs.028009. View

14.

Ishigami S, Arigami T, Uenosono Y, Matsumoto M, Okumura H, Uchikado Y . Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer. Cancer Immunol Immunother. 2012; 61(10):1663-9. PMC: 11028633. DOI: 10.1007/s00262-012-1225-5. View

15.

Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I . The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 2008; 56(3):181-91. DOI: 10.1007/s00005-008-0018-1. View

16.

Zhou S, Shen Z, Wang Y, Ma H, Xu S, Qin J . CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One. 2013; 8(9):e74430. PMC: 3764061. DOI: 10.1371/journal.pone.0074430. View

17.

Zhou S, Chen L, Qin J, Li R, Tao H, Zhen Z . Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity. PLoS One. 2013; 8(9):e73952. PMC: 3759453. DOI: 10.1371/journal.pone.0073952. View

18.

Huang Y, Wang F, Wang T, Wang Y, Zhu Z, Gao Y . Tumor-infiltrating FoxP3+ Tregs and CD8+ T cells affect the prognosis of hepatocellular carcinoma patients. Digestion. 2012; 86(4):329-37. DOI: 10.1159/000342801. View

19.

Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G . Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis. Br J Cancer. 2014; 110(6):1595-605. PMC: 3960618. DOI: 10.1038/bjc.2014.46. View

20.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View